Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

[1]  J. Shaffer,et al.  Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. , 1997, Clinical chemistry.

[2]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[3]  E. Metter,et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.

[4]  L. Shamel,et al.  Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. , 1996, Urology.

[5]  J. Pannek,et al.  The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. , 1996, Urology.

[6]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.

[7]  J. Oesterling,et al.  In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. , 1996, Urology.

[8]  E. Metter,et al.  Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. , 1996, Urology.

[9]  A. Partin,et al.  The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. , 1996, The Urologic clinics of North America.

[10]  W. Catalona,et al.  Racial differences in a prostate cancer screening study. , 1996, The Journal of urology.

[11]  U. Stenman,et al.  Significance of free and bound prostate-specific antigen , 1996 .

[12]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[13]  A. Partin,et al.  Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. , 1996, The Journal of urology.

[14]  H. Klocker,et al.  Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen , 1996, Cancer.

[15]  T. Stamey,et al.  A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. , 1996, The Journal of urology.

[16]  J. Oesterling,et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. , 1996, Urology.

[17]  C. Cuny,et al.  Evaluation of a two-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. , 1996, Clinical chemistry.

[18]  S. Loening,et al.  Analytical performance and clinical validity of two free prostate-specific antigen assays compared. , 1996, Clinical chemistry.

[19]  U B Seiffert,et al.  Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. , 1996, Clinical chemistry.

[20]  J. Hugosson,et al.  Reference range of prostate-specific antigen after transurethral resection of the prostate. , 1996, Urology.

[21]  J. Oesterling,et al.  Ejaculation increases the serum prostate-specific antigen concentration. , 1996, Urology.

[22]  C. Cuny,et al.  Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. , 1996, Urology.

[23]  N. Vogelzang.  Comprehensive Textbook of Genitourinary Oncology , 1996 .

[24]  B. G. Blijenberg,et al.  The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. , 1995, Urology.

[25]  B. G. Blijenberg,et al.  The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. , 1995, Urology.

[26]  F. Mostofi,et al.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.

[27]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[28]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[29]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[30]  J. Oesterling,et al.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. , 1995, Urology.

[31]  Allen C. Goodman,et al.  Economic considerations of prostate cancer. The role of detection specificity and biopsy reduction , 1995 .

[32]  J. Oesterling,et al.  Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. , 1995, British journal of urology.

[33]  R. Kane,et al.  Cost‐effective prostate cancer detection. Reduction of low‐yield biopsies , 1994 .

[34]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[35]  H. C. Graves,et al.  Standardization of immunoassays for prostate‐specific antigen. A problem of prostate‐specific antigen complexation or a problem of assay design? , 1993, Cancer.

[36]  H. Lilja.  Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. , 1993, The Urologic clinics of North America.

[37]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[38]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[39]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[40]  W. Catalona,et al.  Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. , 1992, The Journal of urology.

[41]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.

[42]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[43]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[44]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[45]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[46]  G. Murphy,et al.  Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. , 1982, The Journal of urology.

[47]  D. Ornstein,et al.  Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. , 1997, The Journal of urology.

[48]  A. Semjonow,et al.  Discordance of assay methods creates pitfalls for the interpretation of prostate‐specific antigen values , 1996, The Prostate. Supplement.

[49]  B. Tombal,et al.  Free to total prostate‐specific antigen (PSA) ratio is superior to total‐PSA in differentiating benign prostate hypertrophy from prostate cancer , 1996, The Prostate. Supplement.

[50]  A. Partin,et al.  Clearance rate of serum‐free and total PSA following radical retropubic prostatectomy , 1996, The Prostate. Supplement.

[51]  M. Segers,et al.  Review on the simultaneous determination of total prostate‐specific antigen and free prostate‐specific antigen , 1996, The Prostate. Supplement.

[52]  W. Catalona.  Clinical utility of measurement free and total prostate‐specific antigen (PSA): A review , 1996, The Prostate. Supplement.

[53]  James T. Wu.  Assay for prostate specific antigen (PSA): Problems and possible solutions , 1994, Journal of clinical laboratory analysis.

[54]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[55]  G. Murphy,et al.  Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. , 1982, Journal of the National Cancer Institute.